New hope for advanced colon cancer: immune drugs shrink tumors in biomarker-positive patients
NCT ID NCT02060188
First seen Nov 06, 2025 · Last updated May 02, 2026 · Updated 22 times
Summary
This study tested the drug nivolumab, alone or with other cancer drugs, in 385 people whose colon cancer had returned or spread. It focused on patients with a specific genetic marker called MSI-H. The goal was to see if the treatment could shrink tumors. While not a cure, the approach aims to control the disease and improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MICROSATELLITE-STABLE COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 0001
San Francisco, California, 94115, United States
-
Local Institution - 0002
Boston, Massachusetts, 02114, United States
-
Local Institution - 0003
Houston, Texas, 77030-4009, United States
-
Local Institution - 0004
Los Angeles, California, 90033, United States
-
Local Institution - 0005
Portland, Oregon, 97213, United States
-
Local Institution - 0006
Nashville, Tennessee, 37232, United States
-
Local Institution - 0008
Atlanta, Georgia, 30322, United States
-
Local Institution - 0010
Madrid, 28050, Spain
-
Local Institution - 0011
Seville, 41013, Spain
-
Local Institution - 0012
Madrid, Madrid, 28009, Spain
-
Local Institution - 0013
Pittsburgh, Pennsylvania, 15232, United States
-
Local Institution - 0016
Toronto, Ontario, M5G 1X5, Canada
-
Local Institution - 0018
Brussels, 1090, Belgium
-
Local Institution - 0019
Brussels, 1000, Belgium
-
Local Institution - 0020
Leuven, 3000, Belgium
-
Local Institution - 0022
Dublin, 0, Ireland
-
Local Institution - 0023
Dublin, 0, Ireland
-
Local Institution - 0024
Durham, North Carolina, 27710, United States
-
Local Institution - 0025
Paris, 75571, France
-
Local Institution - 0027
Edmonton, Alberta, T6G 1Z2, Canada
-
Local Institution - 0028
Gilbert, Arizona, 85234, United States
-
Local Institution - 0029
Winston-Salem, North Carolina, 27103, United States
-
Local Institution - 0030
Candiolo, Torino, 10060, Italy
-
Local Institution - 0032
Padova, Padova, Italy
-
Local Institution - 0033
Galway, 0, Ireland
-
Local Institution - 0034
Minneapolis, Minnesota, 55407, United States
-
Local Institution - 0035
Modena, 41124, Italy
-
Local Institution - 0036
Boston, Massachusetts, 02114, United States
-
Local Institution - 0037
Melbourne, Victoria, 3000, Australia
-
Local Institution - 0039
Southport, Queensland, 4215, Australia
-
Local Institution - 0040
Westmead, New South Wales, 2145, Australia
-
Local Institution - 0041
Allentown, Pennsylvania, 18103, United States
Conditions
Explore the condition pages connected to this study.